GHSI vs. CMMB, ATHE, AEZS, ADXN, MTEM, GRTX, ERNA, ABVC, MIRA, and MBRX
Should you be buying Guardion Health Sciences stock or one of its competitors? The main competitors of Guardion Health Sciences include Chemomab Therapeutics (CMMB), Alterity Therapeutics (ATHE), Aeterna Zentaris (AEZS), Addex Therapeutics (ADXN), Molecular Templates (MTEM), Galera Therapeutics (GRTX), Eterna Therapeutics (ERNA), ABVC BioPharma (ABVC), MIRA Pharmaceuticals (MIRA), and Moleculin Biotech (MBRX). These companies are all part of the "pharmaceutical preparations" industry.
Chemomab Therapeutics (NASDAQ:CMMB) and Guardion Health Sciences (NASDAQ:GHSI) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, valuation, media sentiment, dividends, analyst recommendations, community ranking, institutional ownership and profitability.
Chemomab Therapeutics presently has a consensus target price of $5.67, indicating a potential upside of 557.92%. Given Guardion Health Sciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe Chemomab Therapeutics is more favorable than Guardion Health Sciences.
Guardion Health Sciences received 46 more outperform votes than Chemomab Therapeutics when rated by MarketBeat users. Likewise, 67.39% of users gave Guardion Health Sciences an outperform vote while only 61.54% of users gave Chemomab Therapeutics an outperform vote.
46.1% of Chemomab Therapeutics shares are held by institutional investors. Comparatively, 20.2% of Guardion Health Sciences shares are held by institutional investors. 11.9% of Chemomab Therapeutics shares are held by company insiders. Comparatively, 1.3% of Guardion Health Sciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Guardion Health Sciences has a net margin of 0.51% compared to Guardion Health Sciences' net margin of 0.00%. Chemomab Therapeutics' return on equity of 2.01% beat Guardion Health Sciences' return on equity.
Chemomab Therapeutics has a beta of 0.39, indicating that its share price is 61% less volatile than the S&P 500. Comparatively, Guardion Health Sciences has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500.
In the previous week, Chemomab Therapeutics had 8 more articles in the media than Guardion Health Sciences. MarketBeat recorded 12 mentions for Chemomab Therapeutics and 4 mentions for Guardion Health Sciences. Guardion Health Sciences' average media sentiment score of 0.52 beat Chemomab Therapeutics' score of 0.34 indicating that Chemomab Therapeutics is being referred to more favorably in the media.
Guardion Health Sciences has higher revenue and earnings than Chemomab Therapeutics. Chemomab Therapeutics is trading at a lower price-to-earnings ratio than Guardion Health Sciences, indicating that it is currently the more affordable of the two stocks.
Summary
Guardion Health Sciences beats Chemomab Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Guardion Health Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for GHSI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GHSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Guardion Health Sciences Competitors List
Related Companies and Tools
